Education
About Us
Working with TipRanks
Follow Us
IGC Pharma (DE:IGS1)
FRANKFURT:IGS1
IGS1 Analyst Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IGS1 Stock 12 Month Forecast
Average Price Target
€4.04
▲(1342.81% Upside)
| Highest Price Target€4.04 | Average Price Target€4.04 | Lowest Price Target€4.04 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Ascendiant
€3.83→€4.04
Buy
1342.81%
Upside
Reiterated
12/08/25
We are adjusting our FY26 estimates for revenue to $0.9 million, from $1.5 million, but maintaining it for EPS of $(0.08). Reported positive interim results: In March 2024, IGC reported results of an interim analysis of its ongoing Phase 2 trial for IGC-AD1 as a treatment for Agitation in dementia from Alzheimer’s Disease (AAD). The interim data demonstrates a clinical and statistically significant reduction in agitation compared to placebo in patients with Alzheimer’s disease. Over 50% patient enrollment: The company has recently (in September) achieved over 50% patient enrollment in the Phase 2 CALMA trial of IGC-AD1 for agitation associated with Alzheimer’s dementia. The company is planning to complete the trial in early (first half) 2026.
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Ascendiant
€3.83→€4.04
Buy
1342.81%
Upside
Reiterated
12/08/25
We are adjusting our FY26 estimates for revenue to $0.9 million, from $1.5 million, but maintaining it for EPS of $(0.08). Reported positive interim results: In March 2024, IGC reported results of an interim analysis of its ongoing Phase 2 trial for IGC-AD1 as a treatment for Agitation in dementia from Alzheimer’s Disease (AAD). The interim data demonstrates a clinical and statistically significant reduction in agitation compared to placebo in patients with Alzheimer’s disease. Over 50% patient enrollment: The company has recently (in September) achieved over 50% patient enrollment in the Phase 2 CALMA trial of IGC-AD1 for agitation associated with Alzheimer’s dementia. The company is planning to complete the trial in early (first half) 2026.
Best Analysts Covering IGC Pharma
3 Months
xxx
Success Rate
3/7 ratings generated profit
Average Return
+2.96%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of +2.96% per trade.
1 Year
Success Rate
2/7 ratings generated profit
Average Return
-10.71%
a rating ―
Copying Edward Woo's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -10.71% per trade.
2 Years
xxx
Success Rate
0/7 ratings generated profit
Average Return
-25.69%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -25.69% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IGS1 Analyst Recommendation Trends
Rating
Oct 25
Nov 25
Dec 25
Jan 26
Feb 26
Strong Buy
1
0
1
1
1
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
0
1
1
1
Each month's total comprises the sum of three months' worth of ratings.
IGS1 Financial Forecast
IGS1 Stock Forecast FAQ
What is DE:IGS1’s average 12-month price target, according to analysts?
Based on analyst ratings, IGC Pharma’s 12-month average price target is 4.04.
What is DE:IGS1’s upside potential, based on the analysts’ average price target?
IGC Pharma has 1342.81% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IGC Pharma a Buy, Sell or Hold?
IGC Pharma has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is IGC Pharma’s share price target?
The average share price target for IGC Pharma is 4.04. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €4.04 ,and the lowest forecast is €4.04. The average share price target represents 1342.81% Increase from the current price of €0.28.
The highest analyst share price target is €4.04 ,and the lowest forecast is €4.04. The average share price target represents 1342.81% Increase from the current price of €0.28.
What do analysts say about IGC Pharma?
IGC Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of IGC Pharma?
To buy shares of DE:IGS1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.